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An intrachromosomal duplication containing the PMP22 gene is
associated with the human hereditary peripheral neuropathy
Charcot-Marie-Tooth disease type 1A, and PMP22 overexpres-
sion as a consequence of increased PMP22 gene dosage has
been suggested as causative event in this frequent disorder of
peripheral nerves. We have generated transgenic mice that
carry additional copies of the pmp22 gene to prove that in-
creased PMP22 gene dosage is sufficient to cause PNS myelin
deficiencies. Mice carrying approximately 16 and 30 copies of
the pmp22 gene display a severe congenital hypomyelinating
neuropathy as characterized by an almost complete lack of
myelin and marked slowing of nerve conductions. Affected
nerves contain an increased number of nonmyelinating
Schwann cells, which do not form onion bulbs but align in
association with axons. The mutant Schwann cells are charac-
terized by a premyelination-like state as indicated by the ex-
pression of embryonic Schwann cell markers. Furthermore,
continued Schwann cell proliferation is observed into adult-
hood. We hypothesize that Schwann cells are impaired in their
differentiation into the myelinating phenotype, leading to a dis-
order comparable to severe cases of hereditary motor and
sensory neuropathies. Our findings, combined with the analysis
of heterozygous and homozygous PMP22-deficient mice, indi-
cate that aberrant pmp22 gene copy numbers cause various
forms of myelination defects.
Key words: PMP22; myelin; Schwann cell; dysmyelination;
Charcot-Marie-Tooth disease; gene dosage; transgenic mouse
Mutations affecting the myelin proteins PMP22, Cx32, and P0
have been linked to the peripheral neuropathy Charcot-Marie-
Tooth disease (CMT) (for review, see Suter and Snipes, 1995a).
The most common form (70–80%) of familial and spontaneous
CMT (CMT1A) is associated with a 1.5 megabase intrachromo-
somal duplication on chromosome 17p11.2, which contains the
PMP22 gene (Lupski et al., 1991; Raeymaekers et al., 1991;
Matsunami et al., 1992; Patel et al., 1992; Timmerman et al., 1992;
Valentijn et al., 1992a). Less commonly, nonconservative mis-
sense point mutations within the putative transmembrane regions
of PMP22 have also been found in CMT1A (Valentijn et al.,
1992b; Roa et al., 1993a,b) and the congenital hypomyelinating
peripheral neuropathy Dejerine-Sottas syndrome (DSS) (Roa et
al., 1993c). The morphological abnormalities of these human
disorders are comparable to those found in the natural mouse
mutants Trembler (Tr) and Trembler-J (Tr-J), both of which are
also mutated in the pmp22 gene (Suter et al., 1992a,b; Suter et al.,
1993). Deletions of the same chromosomal segment, which is
duplicated in CMT1A, are linked to hereditary neuropathy with
liability to pressure palsies (HNPP) (Chance et al., 1993), and the
causative role of PMP22 in HNPP has been demonstrated by the
generation of PMP22-deficient mice that exhibit a phenotype
comparable to the human disease (Adlkofer et al., 1995).
PMP22 belongs to a family of hydrophobic proteins with four
potential membrane-associated domains (Spreyer et al., 1991;
Welcher et al., 1991). Structurally, PMP22 resembles proteolipid
protein (PLP), the major myelin protein of the CNS, and an
intriguing parallel exists in the genetics of PMP22 and PLP in that
in both cases, altering gene dosage and point mutations lead to
severe myelin deficiencies (Suter and Patel, 1994; Nave and
Boespflug-Tanguy, 1996). Evidence derived from the analysis of
PMP22-deficient mice and observations in human CMT1A pa-
tients have established that PMP22 is crucial for the correct
development of peripheral nerves, the maintenance of axons, and
the determination of myelin thickness and stability (Adlkofer et
al., 1995). The exact function of PMP22 in the PNS, however,
remains elusive (Suter and Snipes, 1995b).
In vitro experiments have suggested that PMP22, in addition to
its role as a component of compact PNS myelin (Snipes et al.,
1992; Haney et al., 1996), may be involved in the regulation of the
cell cycle and apoptosis (Manfioletti et al., 1990; Fabbretti et al.,
1995; Zoidl et al., 1995). A broad role of PMP22 is supported
further by its widespread expression throughout embryonic mouse
development (Baechner et al., 1995), its gene regulation by a
complex regulatory system including a myelinating Schwann cell-
specific and a ubiquitously expressed promoter (Suter et al.,
1994), and the finding of an extended PMP22 gene family with
high expression in various tissues outside of the PNS (Marvin et
al., 1995; Taylor et al., 1995; Taylor and Suter, 1996).
In this report, we describe the phenotype caused by highly
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increased pmp22 gene dosage in transgenic mice, which leads to a
severe peripheral neuropathy reminiscent of DSS.
MATERIALS AND METHODS
Isolation of a cosmid containing the pmp22 gene. Molecular biology
techniques were performed according to standard protocols. A 129Sv
mouse genomic pTCF cosmid library was screened using a 2 kb BamHI-
EcoRI fragment of the 59-flanking region of the pmp22 gene (59-probe;
see Fig. 1). For the characterization of clones and transgenic animals by
Southern blot analysis, the same 59-probe and an additional 39-probe
[1.1-kb-long SfiI-SacII fragment (Adlkofer et al., 1995)] was used. For the
determination of the transgene copy number, an N-CAM probe (Cremer
et al., 1993) was used as internal standard. Signal intensity values were
determined using the PhosphorImager device (Molecular Dynamics,
Kemsing, UK).
Generation of transgenic mice. The 43 kb insert of cosmid pTCF-6.1 was
released by NruI restriction endonuclease digest and separated on a 0.6%
agarose gel. DNA was isolated using the Biotrap electroelutor (Schlei-
cher & Schuell, Dassel, Germany). DNA was desalted and equilibrated in
the injection buffer (5 mM Tris-HCl, pH 7.5/5 mM NaCl/0.1 mM EDTA),
using a Centricon 30 concentrator (Amicon, Beverly MA), and was
sterile-filtered with a prewashed Ultrafree-MC filter unit (0.22 mm, Mil-
lipore, Bedford MA). The DNA was diluted to 2 ng/ml and microinjected
into the pronucleus by standard procedures. Zygotes were recovered
from the oviduct of superovulated B6C3F1 females mated with males of
the same hybrid. CD2F1 hybrids were used as surrogates.
RNA isolation and Northern blotting. Tissue samples for total RNA
isolation were dissected and immediately snap-frozen in liquid nitrogen
until further processing. RNA was isolated using the TRIzol reagent (Life
Technologies, Gaithersburg, MD) according to the manufacturer’s rec-
ommendations. RNA was resuspended in DEPC-treated water, and the
amount of RNA was determined by measurement of OD(260/280); 10 mg of
RNA was separated on a 1.25% denaturing agarose gel. RNA was blotted
onto a nylon membrane (Hybond-N1, Amersham, Buckinghamshire,
UK) by capillary blotting and immobilized at 808C for 2 hr. After
prehybridization of the membrane, PMP22 and P0 mRNA were detected
by hybridization with the respective radioactively labeled cDNA probe.
For quantitative analysis, band intensity data were collected using the
PhosphorImager device and analyzed with the National Institutes of
Health Image program (public domain program, written by Wayne Ras-
band at National Institutes of Health and available from the Internet by
anonymous FTP from zippy.nimh.nih.gov).
Preparation of sciatic nerve homogenates and Western blot analysis.
Sciatic nerves were removed and immediately snap-frozen in liquid ni-
trogen until processing. Nerves were homogenized in 200 ml of 8 M urea
and cleared from debris at 10,000 3 g for 5 min, and protein concentra-
tion of the supernatant was determined (Bio-Rad protein assay, Bio-Rad,
Richmond, CA). Ten micrograms of protein in sample buffer were
separated on a 12.5% SDS-PAGE gel, and the proteins were transferred
onto a nitrocellulose membrane (Schleicher & Schuell) using a semi-dry
blotting apparatus (Trans-Blot SD semi-dry transfer cell; Bio-Rad).
Transfer efficiency was controlled by Ponceau-S staining of the mem-
brane and by Coomassie brilliant blue staining of the gel. Membranes
were blocked in 2% skimmed milk powder in PBS. Antibodies directed
against PMP22 (Susi 4) (Pareek et al., 1993) or directed against the
myelin protein P0 (P0raba; gift from Dr. M. Filbin, Hunter College, NY,
NY) were both applied at a dilution of 1:1000 at 48C for 16 hr. Secondary
antibodies (horse radish peroxidase-coupled polyclonal goat anti-rabbit
antisera; Sigma, St. Louis, MO) at a dilution of 1:5000 were applied for
1–2 hr at room temperature after fourfold washing of the membrane with
PBS/0.2% Tween 20. After repeated washing to remove excess secondary
antibodies, detection of the immunoreactive products was performed by
visualization of chemiluminescence (ECL Western blot detection re-
agents; Amersham, Arlington Heights, IL) on x-ray films (Fuji, Stam-
ford, CT).
Light microscopic analysis. Six micrometer frozen sections from the
quadriceps muscle were stained by NADH tetrazolium reductase histo-
chemistry according to standard protocols and analyzed and photo-
graphed on an Axiophot microscope. Ten micrometer cross-cryosections
of the sciatic nerves of 8-, 21-, and 70-d-old wild-type and PMP22-
transgenic mice were stained with 49,6-diamidine-29-phenylindole dihy-
drochloride (DAPI) (Boehringer Mannheim, Mannheim, Germany) ac-
cording to the manufacturer’s recommendations. Photographic slides
were analyzed using a Power Macintosh 6100/60 computer using the
National Institutes of Health Image program (see above). For semithin
sections, nerves embedded as for electron microscopy were cut in 2 mm
sections and stained with alkaline toluidine blue.
Immunohistology. The localization of low-affinity NGF receptor
(LNGFR), N-CAM, L1, and glial fibrillary acidic protein (GFAP) was
carried out by indirect immunofluorescence on fresh-frozen sections of
femoral quadriceps nerves as described (Giese et al., 1992; Montag et
al., 1994).
Proliferation analysis.Mice were injected with 5-bromo-29-deoxyuridine
(BrdU) intraperitoneally (50 mg/kg in PBS) at various time points (21 and
70 d after birth). The animals were killed with an overdose of Nembutal
(Abbott Laboratories, North Chicago, IL) 18 hr after the administration
of the nucleotide analog that allows for immunocytochemical detection of
proliferating cells after incorporation into replicating DNA (Gratzner,
1982). Sciatic nerves were fixed in situ for 20 min, postfixed in 4%
paraformaldehyde (PFA) in PBS, and embedded in paraffin. BrdU im-
munocytochemistry was carried out using a monoclonal, biotinylated
antibody (1:50; Caltag, San Francisco, CA).
Tissue preservation and electron microscopy. Electron microscopy of
sciatic nerves of transcardially perfused experimental and control mice
(2% PFA and 2% glutaraldehyde in 0.1 M cacodylate buffer) was per-
formed according to Adlkofer et al. (1995).
Electrophysiological analysis. The methods for electrophysiological
analysis have been described (Adlkofer et al., 1995). Six PMP22-
transgenic and five wild-type control animals (sibling of two litters) were
examined. Latencies, amplitudes, duration of the compound muscle ac-
tion potential (CMAP or M-response) (Kimura, 1989), and the F-wave
elicitability, latency, and duration were analyzed in the sciatic nerve
(Hartung et al., 1988; Kimura, 1989). Because CMAP amplitudes were
very low in PMP22-transgenic mice, 10–20 M-responses in these animals
were averaged. Nerve conduction velocities of control mice were similar
to those reported earlier (Low and McLeod, 1975; Pollard and McLeod,
1980; Montag et al., 1994; Adlkofer et al., 1995). Double-sided U test
(significance level 0.05) was used to assess the statistical significance of
differences in the nerve conduction studies between PMP22-transgenic
and control mice (Instat, GraphPad, San Diego, CA).
RESULTS
Isolation of a cosmid clone containing the mouse
genomic pmp22 gene and generation of
transgenic mice
On the basis of the examination of mouse genomic DNA by
Southern blot analysis, we estimated that the pmp22 gene spans
;40 kb (data not shown). Thus, we decided to screen a mouse
cosmid library to isolate a full-length mouse genomic pmp22
clone. Using the 59-flanking region of the pmp22 gene as a probe
(59-probe containing exons 1b and 2) (Fig. 1 A), we isolated five
independent overlapping cosmid clones ranging in their insert size
from 32.5 to 42.5 kb (data not shown). One of these clones
(pTCF-6.1; insert size, 42.5 kb) (Fig. 1 A) contained the entire
pmp22 gene flanked by ;7 kb upstream nontranscribed region
and .4 kb downstream nontranscribed region. The 59-
untranslated exons 1a and 1b were mapped by Southern blot
analysis, and identity was confirmed by DNA sequencing
(Adlkofer et al., 1995) (data not shown). Exon 5 was localized by
Southern blot analysis using a probe specific for the 39-flanking
region (Adlkofer et al., 1995) (39-probe in Fig. 1 A), and the
presence of the complete exon 5 was confirmed by PCR analysis
(data not shown). The purified 43 kDa NruI-excised insert of
pTCF-6.1, which included ;0.2 kb of vector sequences on either
end, was used for microinjection into fertilized mouse oocytes of
the F1 hybrid strain B6C3F1 to generate PMP22-transgenic mice.
Copy number of pmp22 genes in PMP22-transgenic
mouse lines
PMP22-transgenic mice were identified by Southern blot analysis
of BamHI-digested mouse genomic DNA using the 59-probe
described above (Fig. 1B). Quantitative analysis using an internal
control standard (see Materials and Methods) and phosphor-
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imaging identified three transgenic founder mice (out of 17 viable
progenies) with gene copy numbers of approximately 16
[TgN(pmp22Ge)248Zbz 5 TgN248; nomenclature according to
ILAR News, 1992] and 30 [TgN(pmp22Ge)247Zbz 5 TgN247
and TgN(pmp22Ge)249Zbz5 TgN249]. Detailed additional anal-
ysis correlated with concatemeric head-to-tail integration of the
transgenes (data not shown). Stable transgenic lines were estab-
lished from all three founder animals, and no significant differ-
ences were observed in the phenotype and pathology between the
three lines. Thus, the following analysis shows representative data
obtained using line TgN248 (unless indicated differently).
Characterization of PMP22 expression in
PMP22-transgenic mice
Northern blot analysis was performed to examine the regulation
of PMP22 expression in transgenic animals. In agreement with the
tissue-specific expression pattern of the endogenous pmp22 gene
in wild-type control mice, no PMP22 mRNA was detected in
kidney, stomach, thymus, spleen, and liver of transgenic animals at
postnatal day 21 (data not shown). Low expression of PMP22
mRNA was found in the heart and the lung. Although no over-
expression was observed in the lung of PMP22-transgenic mice
(data not shown), a relative PMP22 overexpression of approxi-
mately twofold was found in the heart (for examples, see Fig. 2A,
lanes 1–4), but no defects could be detected in this tissue by
histological analysis (data not shown). P0 expression was not
detectable, demonstrating that PMP22 expression in the heart is
not attributable to innervation. As expected on the basis of the
observed severe myelin deficiency in sciatic nerves of PMP22-
transgenic mice (see below), PMP22 mRNA was decreased to
54 6 32% (n 5 5) if normalized to the amount of total RNA and
compared with wild-type animals (for example, see lanes 5 and 6
in Fig. 2 A,C). Because PMP22 and P0 show a similar regulation
in myelinating Schwann cells, we used a cDNA probe specific to
P0 as an internal standard for myelin-specific genes and reprobed
the Northern blot membranes. On the basis of the decreased
expression of the P0 mRNA (26 6 7%; n 5 6) in PMP22-
transgenic animals (lanes 5 and 6 in Fig. 2B,C), an approximately
twofold overexpression of PMP22 mRNA was observed in the
sciatic nerves of 21-d-old PMP22-transgenic animals when stan-
dardized to the levels of P0 mRNA expression. Western blot
analysis using antibodies directed against PMP22 or P0 revealed a
dramatic decrease in protein expression of both myelin proteins in
PMP22-transgenic mice (Fig. 2D). Interestingly, this reduction
was much more pronounced than at the mRNA level observed
previously in Northern blot analysis.
Behavioral characteristics of PMP22-transgenic mice
Two of the founder mice (TgN247 and TgN249) showed a distinct
phenotype characterized mainly by an unsteady gait, a trait that
was stably transmitted to the progeny. The founder of TgN248 was
not visibly affected and yielded only 27% (n 5 168) transgenic
progeny in the F1 generation (which was phenotypically and
pathologically not distinguishable from TgN247 and TgN249),
indicative of a mosaic animal. In general, PMP22-transgenic
males show poor breeding efficiency, and the litter size of PMP22-
transgenic females was reduced significantly (data not shown).
First signs of behavioral abnormalities appear 2 weeks after
birth as manifested by a slight shivering of the animals, which is
most obvious at the head. At 4 weeks, an unsteady gait becomes
apparent. Signs of muscle atrophy, in the form of distal body
shape slenderness, are present at the age of 2–3 months but are
variable in extent between individual animals. Progression in
severity of the disease with age often culminates in pronounced
Figure 2. Analysis of the expression of PMP22 and P0. Northern blot
analysis of PMP22-transgenic and wild-type mice (A–C). The same blot
was hybridized first with a PMP22 cDNA probe (A) and subsequently with
P0 cDNA probe (B). Ethidium bromide-stained agarose gel (C; 18S RNA)
is shown as quantitation control. RNA was isolated from heart (lanes 1–4)
and from sciatic nerves (lanes 5 and 6) of 21-d-old PMP22-transgenic mice
(lanes 1, 3, and 5) and wild-type (lanes 2, 4, and 6) siblings (note that the
exposure times of the different blots and probes were not identical).
Western blot analysis of PMP22-transgenic and wild-type mice (D). Crude
sciatic nerve homogenates (20 mg of protein) of PMP22-transgenic mice
(lanes 1 and 3; TgN248) and wild-type littermates (lanes 2 and 4) were
separated on 12.5% SDS-PAGE and blotted to nitrocellulose membranes.
Proteins were probed with antibodies specific for PMP22 (lanes 1 and 2)
or P0 (lanes 3 and 4).
Figure 1. Generation of PMP22-transgenic mice. A, Struc-
ture of the genomic PMP22 cosmid clone pTCF-6.1. Identi-
fied exons are indicated by filled boxes and numbered below;
cosmid-derived sequences are represented by open boxes.
The DNA probes used for identification and characterization
of the clone (39- and 59-probes) are indicated by thick lines.
The 43-kb-long NruI fragment of pTCF-6.1 was purified on a
0.6% agarose gel, isolated by electroelution, and microin-
jected into fertilized oocytes. S, SalI; K, KpnI; B, BamHI; N,
NruI. B, Southern blot analysis of BamHI-digested genomic
DNA of PMP22-transgenic and wild-type founder mice using
the 59-probe (lanes 2 and 3 are wild type, and lanes 1, 4, and
5 represent the transgenic lines TgN247, TgN248, and
TgN249, respectively).
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paralysis of the hindlimbs. Generally, the lifespan of PMP22-
transgenic mice exceeds 8 months.
Electrophysiology
Motor nerve conduction studies in all examined 10- to 12-week-
old PMP22-transgenic mice showed the typical electrophysiolog-
ical signs of a severe dysmyelinating polyneuropathy, i.e., in-
creased latencies and decreased amplitudes of CMAP responses
with temporal dispersion in both the sciatic and facial nerves (Fig.
3). Motor nerve conduction velocities were reduced severely in
the sciatic nerve of PMP22-transgenic mice. In general, a large
inter-individual variability in the severity of the electrophysiolog-
ical impairment in PMP22-transgenic mice was observed, for
example, with facial nerve M-response latencies ranging from 3.8
msec to as much as 14.2 msec (range of normal control mice,
0.8–1.24 msec; see Fig. 3). We could not obtain M-responses after
proximal sciatic nerve stimulation in three PMP22-transgenic
mice, indicating either severe dysmyelination or complete conduc-
tion failure. F-wave studies showed reproducible late compound
motor responses in only two PMP22-transgenic mice, with a highly
increased latency (37 and 42.5 msec as compared with a mean 6
SD of 4.1 6 0.2 msec in five control mice after proximal sciatic
nerve stimulation). Threshold stimulus values were increased sig-
nificantly in the facial and sciatic nerve (distal stimulation site) of
PMP22-transgenic mice (data not shown), indicating possible
axonal damage. Reliable measurements of the absolute refractory
time of the facial nerve could not be obtained in PMP22-
transgenic mice because of M-response polyphasia and signal
background. We also could not record mixed afferent nerve po-
tentials in the sciatic nerve of PMP22-transgenic mice even after
averaging .100 stimuli, indicating either complete conduction
failure or profound dispersion of nerve potential components
leading to phase cancellation attributable to severe dysmyelina-
tion. This latter finding indicates that afferent fibers are affected
similarly to motor fibers.
Morphological analysis by light microscopy
Two micrometer semithin cross-sections of the sciatic nerve were
prepared and stained with alkaline toluidine blue. No detectable
myelin was seen in 21-d-old PMP22-transgenic mice (compare
Fig. 4a and 4a9) or in 10- or 70-d-old animals (data not shown).
Abnormal myelination in nerves of wild-type animals was never
observed.
The examination of other organs and tissues did not reveal any
differences between PMP22-transgenic mice and wild-type litter-
mates, with the exception of neurogenic muscle atrophy (see
below) and decreased body fat (probably attributable to feeding
difficulties).
Characterization of Schwann cell antigen expression
To characterize the differentiation status of Schwann cells over-
expressing PMP22, the expression of a set of proteins typically
associated with Schwann cells of a pre- or nonmyelinating state
was investigated on fresh-frozen sections of peripheral nerves of
wild-type and mutant adult mice. These markers include the cell
surface components low-affinity NGF receptor (LNGFR),
N-CAM, and L1, and the cytoskeletal component GFAP (Jessen
and Mirsky, 1991; Martini, 1994).
We have chosen the femoral quadriceps nerve for this analysis
because it contains only a few nonmyelinating axon-Schwann cell
units, which express these molecules in the wild type at high levels
(Fig. 4 b–d) (Giese et al., 1992). In mutant mice, a strong upregu-
lation of LNGFR by most, if not all, Schwann cells was charac-
teristic (Fig. 4b9). N-CAM was upregulated by the developmen-
tally abnormal Schwann cells of the mutant but to a significantly
lower degree than LNGFR (Fig. 4c9). L1 was weakly upregulated
by some abnormal Schwann cells of the nerve (Fig. 4d9). Inter-
estingly, both N-CAM and L1 were also upregulated by nonmy-
elinating axon-Schwann cell units (Fig. 4c9,d9), suggesting that
PMP22 overexpression might have an additional subtle effect on
this Schwann cell type, which has recently been shown to express
low levels of endogenous PMP22 (Haney et al., 1996). Finally, the
cytoskeletal component GFAP was confined to nonmyelinating
Schwann cells in the wild type and was weakly upregulated in the
mutant nerve (not shown).
Electron microscopy
In sciatic nerves of 10-, 21-, and 72-d-old wild-type mice, large
caliber axons were surrounded by compact myelin (Fig. 5a). All
Schwann cells formed a typical basal lamina, and endoneurial
collagen fibrils were abundant between the axon-Schwann cell
units.
Morphology of the sciatic nerves of the corresponding mutant
littermates was very different and showed evidences of a severe
disruption of myelin formation (Figs. 5b–d). In 10-d-old mice,
myelin sheaths were completely absent, although most of the
Schwann cells had formed a basal lamina and had acquired a 1:1
ratio with their axons (Fig. 5b). In rare cases, two or more
Schwann cells were associated with one central axon (data not
shown). No degenerating myelin or myelin debris was detectable
in 10-d-old mice, suggesting that the absence of myelin was not
the result of myelin degeneration but the consequence of dis-
rupted myelin formation from the onset. In 21-d-old animals, the
situation was similar to that seen in 10-d-old mice, with three
exceptions (Fig. 5c). First, the cytoplasm of most of the Schwann
cells associated with large caliber axons was much more electron-
Figure 3. Nerve conduction analysis of PMP22-transgenic mice and wild-
type littermates. Top, Summary of the results of the nerve conduction
studies in the facial (left) and sciatic nerves (right; Mean 6 SD; n 5
number of animals analyzed) of 10-week-old PMP22-transgenic and wild-
type control mice. We were unable to elicit proximal sciatic nerve CMAP
responses in two PMP22-transgenic mice. Therefore, the conduction ve-
locity in the sciatic nerve could be determined in only three mice of this
group and may therefore be slightly overestimated. Bottom, Redrawn
original recordings of CMAP responses after stimulation of the facial
nerve (left) and the distal sciatic nerve (right) of a 79-d-old control mouse
(top row) and of a 79-d-old PMP22-transgenic sibling (bottom row). Note
the different time and amplitude scales. Recordings were reproducible on
repeated stimulation.
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Figure 4. Assessment of myelination in semithin sections and immunohistological analysis. Cross-sections (2 mm) of 21-d-old wild-type (a) and
PMP22-transgenic mice (a9) were stained with toluidine blue. Note the lack of detectable myelin (a9). Immunohistological localization of the cell surface
molecules LNGFR (b, b9), N-CAM (c, c9), and L1 (d, d9) in femoral quadriceps nerves of adult wild-type (b–d) and mutant mice (b9–d9). Although
LNGFR is prominently upregulated in mutant mice (b, b9), N-CAM is moderately (c, c9) and L1 weakly increased (d, d9). Note that the nonmyelinating
axon-Schwann cell units also are labeled stronger for N-CAM and L1 in the mutants (c9, d9) than in the wild-type mice (c, d). Arrow in c marks the weakly
N-CAM-immunoreactive perineurium of a wild-type nerve. Scale bars, 50 mm.
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dense than that of 10-d-old mutant mice or 21-d-old wild-type
littermates forming myelin. Second, each axon-Schwann cell unit
was surrounded by multiple “pockets” of basal laminae, which
usually contained very thin collagen fibrils, indicative of Schwann
cell origin (Bunge et al., 1986). Occasionally, in some of these
supernumerary pockets, dark Schwann cell processes were detect-
able. Third, a few larger-caliber axons were surrounded by unusu-
ally thin sheaths of compacted myelin. Such profiles were always
surrounded by multiple pockets of Schwann cell basal laminae.
Rarely, degenerating myelin and myelin debris were detectable
(data not shown). At postnatal day 72, compact myelin was no
longer seen, which is in line with the occurrence of some degen-
erating myelin profiles in 21-d-old mice (Fig. 5d, and data not
shown). Supernumerary Schwann cell basal laminae were still
frequent, but often appeared disorganized or even disrupted and
only very rarely contained Schwann cell processes (Fig. 5d).
The finding of abnormally thin but structurally intact myelin in
21-d-old animals may be explained by somatic transgene inactiva-
tion, like methylation or chromosomal rearrangements, that al-
lowed some Schwann cells to escape from PMP22 overexpression.
Figure 5. Ultrastructural examination
of sciatic nerves. Electron microscopy of
sciatic nerves of 10- (a, b), 21- (c), and
72-d-old (d) wild-type (a) or PMP22-
transgenic mice (b–d; TgN248). In 10-d-
old wild-type mice (a), larger-caliber ax-
ons (A) are associated with compact
myelin (M), whereas in transgenic litter-
mates (b), larger-caliber axons are en-
sheathed by Schwann cells, which do not
form myelin. Arrowhead points to
Schwann cell basal lamina. In 21-d-old
PMP22-transgenic mice (c), most of the
larger-caliber axons are associated with
Schwann cells, which do not form myelin;
however, ;10% of the axons having ac-
quired a 1:1 ratio with Schwann cells are
surrounded by a thin sheath of compact
myelin (M). Note the prominent pockets
of Schwann cell basal laminae (arrow-
heads), which are occasionally filled with
Schwann cell processes of high electron
density (double arrowheads). A9, Axons
devoid of an ensheathing Schwann cell
are found that are surrounded by pockets
of basal laminae, indicative of the previ-
ous presence of a Schwann cell (arrow-
heads). In 72-d-old PMP22-transgenic
mice (d), larger-caliber axons (A) are al-
ways associated with Schwann cells de-
void of myelin. Profiles of supernumerary
Schwann cell basal laminae (arrowheads)
are seen consistently but appear less
prominent than in 21-d-old mice. Scale
bars, 1 mm.
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Because such inactivation processes are likely to be only partially
effective, the remaining PMP22 overexpression level may still lead
to an unstable myelin structure that is rapidly degraded, similar to
the observed pathology of CMT1A patients with comparably mild
PMP22 overexpression (Gabreels-Festen et al., 1996).
In contrast to the Schwann cells associated with large caliber
axons, the Schwann cells ensheathing small caliber axon groups
were normally organized in mutant mice and were neither of
darker appearance nor surrounded by multiple pockets of basal
laminae (Fig. 5d; data not shown).
Muscle pathology in PMP22-transgenic mice
Histological analysis of the quadriceps muscle of 10-week-old
mice using NADH tetrazolium reductase staining revealed an
even distribution of intermingled type I (dark muscle fibers) and
type II (light muscle fibers) in wild-type animals (Fig. 6A). In
PMP22-transgenic animals, however, extensive fiber-type group-
ing was visible (Fig. 6B), and at more advanced stages, definite
signs of neurogenic atrophy were seen, such as large areas con-
taining mainly atrophic fibers intermingled with smaller groups of
hypertrophic muscle fibers (Fig. 6C). Even at this stage, however,
no muscle fiber degeneration was present, indicating the absence
of any relevant myopathic component in the disease.
Aberrant Schwann cell proliferation in the sciatic nerve
of PMP22-transgenic mice
Isolation of total RNA from the sciatic nerves of PMP22-
transgenic 21-d-old animals consistently yielded double the
amount of RNA compared with that of wild-type littermates,
indicating a potential increase in cell number (data not shown).
Ten micrometer frozen cross- and longitudinal sections of the
sciatic nerves of 8-, 21-, and 70-d-old mice were used to assess cell
number. 49,6-diamidine-29-phenylindole dihydrochloride (DAPI)
staining revealed an approximately twofold increase of nuclei in
8-d-old mutant animals when compared with wild-type littermates
and an approximately fourfold increase in 70-d-old mutant nerves
(Fig. 7). Analysis of longitudinal sections by electron microscopy
showed that most of the supernumerary cells are Schwann cells
that have axonal contact and are aligned along the axon (Fig. 8C);
however, these Schwann cells fail to build up myelin. These results
are in agreement with the microscopic findings that there are no
signs of a significant number of invading macrophages, endoneur-
ial fibroblasts, or supernumerary Schwann cells not in contact with
axons in the sciatic nerves of mutant mice (data not shown).
Proliferation analysis as examined by injection of 5-bromo-29-
deoxyuridine (BrdU) and subsequent immunohistochemical anal-
Figure 7. Cell number in cross-sections of sciatic nerves. Sciatic nerves of 10-week-old wild-type mice (A) and PMP22-transgenic siblings (B) were
analyzed histologically after DAPI staining. Scale bar, 50 mm. Ten micrometer cryosections of PMP22-transgenic and wild-type mice of various ages were
stained with DAPI, and the nuclei were counted (C). The bars indicate the relative surplus of nuclei in the sciatic nerves of PMP22-transgenic mice
compared with wild-type animals. p values (two-tailed Student’s t test) are given.
Figure 6. Histological analysis of the quadriceps muscle of
PMP22-transgenic and wild-type mice. Normal chessboard-
like distribution pattern of types I (slow-twitch muscle, dark)
and II (fast twitch muscle, light) muscle fibers of wild-type
animals (A). PMP22-transgenic animals (B, C) show promi-
nent segregation and grouping of types I and II fibers (B) and
few hypertrophic fibers (arrows) but no significant atrophy.
C, Late stage of neurogenic myopathy with type grouping
and large groups of atrophic fibers. Scale bar, 25 mm.
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ysis of sciatic nerves revealed a robust increase in the number of
proliferating cells in 21-d-old PMP22-transgenic mice compared
with wild-type littermates (Fig. 8A,B). Similar results were ob-
tained in 70-d-old mice (data not shown).
DISCUSSION
We report the characterization of three transgenic mouse lines
that carry additional copies of the pmp22 gene. Each line showed
an identical phenotype in all parameters examined, despite dif-
ferences in the copy number of transgenes. We attribute this
finding to the high number of PMP22 transgenes present, which
probably leads to a massive overdose of PMP22 expression in all
three lines. Nevertheless, we observed only a twofold overexpres-
sion of PMP22 mRNA in the mutant animals relative to the
mRNA levels of the major PNS myelin protein P0. When nor-
malized to total RNA, both PMP22 and P0 mRNA levels were
reduced, and this downregulation was quantitatively even more
pronounced at the protein level, in agreement with the virtually
complete absence of myelin. Interestingly, similar downregula-
tions of P0 mRNA have also been observed in other myelin-
deficient mouse strains with either null mutations in the Krox-20
gene (Topilko et al., 1994) or point mutations in pmp22 (Tr;
Bascles et al., 1992). In PMP22-transgenic mice, the finding of a
twofold absolute overexpression of PMP22 mRNA in heart tissue
suggests that the observed absolute underexpression of PMP22 in
the sciatic nerve is a tissue-specific phenomenon, probably attrib-
utable to the predominant dysmyelination phenotype.
The relatively small overexpression of PMP22 compared with the
level of P0 and the number of transgenes also has been seen in other
transgenic mouse mutants that carry multiple copies of myelin genes,
including PLP and DM20 (Nadon et al., 1994). It is important to
realize, however, that the overexpression of transgenes may vary
considerably throughout development, particularly in PMP22-
transgenic mice, because the observed phenotype indicates that the
critical time period in which overexpression of PMP22 affects
Schwann cell development is right at the start of myelination. In line
with these results, PMP22-deficient mice are delayed significantly in
myelination, suggesting that PMP22-deficiency also affects Schwann
cell differentiation (Adlkofer et al., 1995).
Comparison of the phenotypes of PMP22-transgenic
mice and hereditary peripheral neuropathies
PMP22-transgenic mice reveal that strong overexpression of PMP22
is sufficient to cause a very robust myelin deficiency with the typical
clinical and electrophysiological signs of a severe dysmyelinating
polyneuropathy. This dysmyelination is likely attributable to the
highly increased PMP22 gene dosage, because transgenic rats that
carry a lower copy number of PMP22 transgenes exhibit a more
CMT1A-like demyelinating phenotype, which is characterized by
classical Schwann cell onion bulb formation (Sereda et al., 1996). In
contrast, PMP22-transgenic mice are characterized mainly by com-
plete lack of myelin, Schwann cell proliferation, and the presence of
redundant basal laminae.We interpret these findings such that a high
pmp22 gene dosage in transgenic mice shows the consequences of
one extreme of a continuum of phenotypes associated with different
levels of PMP22 expression. Mice that are completely deficient in
PMP22 develop prominent focal hypermyelination (tomacula) and
subsequent myelin degeneration (Adlkofer et al., 1995). A similar
but less pronounced pathology is observed in mice carrying only one
functional pmp22 copy, which genetically and pathologically mimics
HNPP patients. Three PMP22 gene copies in heterozygous CMT1A
patients (Gabreels-Festen et al., 1996) at first approximation lead to
quite normal myelination followed by demyelination, with a more
severe phenotype in homozygous CMT1A patients (four pmp22 gene
copies) (Killian and Kloepfer, 1979). Finally, the high pmp22 gene
copy number in the mice reported here is characterized by the most
severe defect, essentially showing nearly complete absence of myelin.
Thus, the combined data support the hypothesis that altered PMP22
gene dosage is not compatible with normal Schwann cell develop-
ment and homeostasis.
With respect to human peripheral neuropathies, the morpho-
logical phenotype of PMP22-transgenic mice is almost identical to
a specific subtype of hereditary motor and sensory neuropathies
type III (autosomal recessive HMSN III), which is characterized
Figure 8. Schwann cell proliferation in the sciatic nerve of PMP22-transgenic and wild-type mice. Longitudinal sections (2 mm) of BrdU-labeled sciatic nerves
of 21-d-old wild-type mice (A) and PMP22-transgenic littermates (B). Frequent incorporation of BrdU in PMP22-transgenic mice indicates proliferation of
Schwann cells (arrows in B), whereas only rare signals in the wild type are detectable. Scale bar, 25 mm. Ultrathin longitudinal section of a sciatic nerve of a
10-week-old PMP22-transgenic mouse (C). A large caliber axon (black asterisks) is ensheathed by darkly appearing Schwann cell processes (arrows in C).White
asterisks indicate Schwann cell perikarya with direct contact to the axon. Note that their frequency is unusually high. The two neighboring Schwann cell nuclei
at the left possibly indicate that a Schwann cell mitosis takes place (arrowheads, endoneurial collagen). Scale bar, 5 mm.
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by amyelination and basal lamina onion bulb formation (Gabreel-
Festen et al., 1992; Nara et al., 1995). Recent findings in trans-
genic mice carrying null mutations of the Krox-20 (Schneider-
Maunoury et al., 1993; Topilko et al., 1994) and SCIP genes
(Bermingham et al., 1995) exhibit a phenotype similar to HMSN
III, which may indicate that specific mutations in transcription
factors that are involved in the determination of the myelinating
Schwann cell phenotype are also potential candidate disease
genes. Thus, it is tempting to speculate that mutations in these
transcription factors may lead to a dysregulation of PMP22 gene
expression and in turn to a closely related hypomyelinating phe-
notype as observed in PMP22-transgenic animals.
Consequences of PMP22 overexpression and
comparison to PMP22 point mutations
The phenotype of PMP22-transgenic animals is similar but not
identical to that of Tr mice, which carry a point mutation in the
pmp22 gene (Henry et al., 1983; Henry and Sidman, 1988). Severe
hypomyelination and increased Schwann cell number are the main
common morphological features, and prominent pockets of re-
dundant basal laminae surrounding hypomyelinated axons have
been described in both mouse mutants (Low, 1977). The etiology
of excessive basal laminae is not clear but differs in Tr compared
with PMP22-transgenic mice. During the development of Tr
nerves, supernumerary Schwann cells move away from the axons
and form classical onion bulbs as the result of demyelination,
Schwann cell proliferation, and remyelination. Subsequently,
these redundant Schwann cells are believed to extend sprouts that
later degenerate or retract, leaving basal laminae behind as a
fingerprint of this process (Low, 1977). In contrast, classical cel-
lular onion bulb formation was not observed in PMP22-transgenic
mice, and the supernumerary Schwann cells were found aligned
along the axons. Thus, the detected excessive basal laminae are
likely to be the direct result of proliferation, migration, and
possible transient extensions of Schwann cell processes associated
with axons. Alternatively, the observed redundant basal laminae
might be remnants of Schwann cells that have undergone cell
death, possibly attributable to PMP22 overexpression.
Schwann cell development and proliferation in PNS
myelination mutants
Increased Schwann cell number and aberrant Schwann cell prolifer-
ation into adulthood are common features in PNS hypomyelinating
mutants; however, this phenomenon seems to be caused by different
mechanisms. In longitudinal sections of sciatic nerves of Krox-20 null
mutants, the nuclei of redundant nerve-resident cells appear mainly
spherical and are distributed randomly (Topilko et al., 1994). In
contrast, Schwann cell nuclei in PMP22-transgenic mice retain their
characteristically elongated shape, in agreement with the finding that
supernumerary Schwann cells retain axonal contact. Immunohisto-
logical analysis of PMP22-transgenic nerves reveals a strong upregu-
lation of LNGFR, a moderate increase of N-CAM, and minor
upregulation of L1 and GFAP. This characteristic expression profile
of Schwann cell development markers in combination with the po-
sitions of the supernumerary Schwann cells along single axons indi-
cates that the differentiation state of mutant Schwann cells in
PMP22-transgenic mice closely resembles the characteristics of nor-
mal Schwann cells just before myelination (Jessen andMirsky, 1991).
It is an attractive hypothesis that the mutant Schwann cells begin to
differentiate toward the myelinating phenotype and concomitantly
start to overexpress PMP22 massively (Suter et al., 1994). This pulse
of strong PMP22 overexpression may not allow further differentia-
tion, thereby explaining the dysmyelination phenotype, or possibly
may even cause cell death, as suggested by complementary in vitro
studies (Fabbretti et al., 1995). If the latter speculation is correct, the
observed aberrant proliferation of Schwann cells into adulthood may
provide a mechanism to replace the continuously dying cells.
It should be stressed, however, that the mutant Schwann cells in
PMP22-transgenic mice have established a 1:1 relationship with
large caliber axons and laid down basal laminae. Furthermore, no
morphological abnormalities of nonmyelinating Schwann cells
ensheathing small caliber axons were observed. This is in contrast
to a mouse model with increased Schwann cell death, which is
caused by the expression of the bacterial diphtheria toxin A chain
under the control of the P0 gene promoter (Messing et al., 1992).
Those mutants show a pronounced secondary response of non-
myelinating Schwann cells, including proliferation and retraction
of processes, suggesting a dynamic equilibrium between myelinat-
ing and nonmyelinating Schwann cells.
In summary, although the elucidation of the mechanistic basis
of the observed Schwann cell differentiation defects in mice with
strongly increased pmp22 gene dosage requires additional in vivo
and in vitro studies to clarify the function of PMP22 in normal and
mutant organisms, these animals demonstrate that impaired
Schwann cell differentiation is a likely disease mechanism in
hereditary peripheral neuropathies.
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